To quantify the efficacy of vaccination of infants with bacillus Calmette-Guérin (BCG) against tuberculosis.
MEDLINE with index terms BCG vaccine, tuberculosis, and human ; lists of all known studies provided by experts at the Centers for Disease Control and Prevention, the World Health Organization, and other organizations.
A total of 1264 articles and abstracts were reviewed for details on BCG vaccination, the availability of concurrent vaccinated and unvaccinated groups, and a tuberculosis outcome.
These studies documented a protective effect of 0.83.
In a random-effects regression model of the nine case-control studies, study validity score explained 15% of the heterogeneity among study-estimated protective effects, suggesting that better studies reported greater efficacy.
Three trials and six case-control studies provided some age-specific information that allowed us to examine the duration of BCG efficacy.
Most of this evidence suggested that BCG efficacy may persist through 10 years after infant vaccination.
BCG vaccination of newborns and infants significantly reduces the risk of tuberculosis-by over 50%, on average.
Protection has been observed across many populations, study designs, and forms of tuberculosis.
Rates of protection against cases that are confirmed by laboratory tests, reflecting reduced error in disease classification and consequently more accurate estimates of BCG efficacy, are highest at 83%.
Mots-clés Pascal : Nouveau né, Homme, Nourrisson, Tuberculose, Mycobactériose, Bactériose, Infection, Prévention, Vaccination, BCG, Métaanalyse, Synthèse bibliographique, Evaluation, Immunoprotection
Mots-clés Pascal anglais : Newborn, Human, Infant, Tuberculosis, Mycobacterial infection, Bacteriosis, Infection, Prevention, Vaccination, BCG, Metaanalysis, Bibliographic survey, Evaluation, Immunoprotection
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0413112
Code Inist : 002B05B02O. Création : 01/03/1996.